@EmboMolMed My mom received #Olaparib in a clinical trial (PAOLA-1). It saved her life. Now, we are collecting donations to get Olaparib as a long-time treatment. If you want to help, please do so, thanks: https://www.gofundme.com/f/olaparib-als-erhaltungstherapie-gegen-krebs?utm_campaign=m_pd+share-sheet&utm_content=undefined&utm_location=undefined&utm_medium=copy_link_all&utm_source=customer&utm_term=undefined

@DocCheck Meine Mama hat #Olaparib in einer klinischen Studie gegen ein Ovarialkarzinom (Stadium Figo IV) erhalten. Es hat ihr sehr gut geholfen. Wir kämpfen nun darum, Olaparib als Erhaltungstherapie zu erhalten. Wer helfen möchte, wir freuen uns über jede Spende: https://www.gofundme.com/f/olaparib-als-erhaltungstherapie-gegen-krebs?utm_campaign=m_pd+share-sheet&utm_content=undefined&utm_location=undefined&utm_medium=copy_link_all&utm_source=customer&utm_term=undefined

💊💉 #olaparib
SmPC for Lynparza 150 mg film-coated tablets has been updated with changes to sections 4.8 Undesirable effects; 7. Marketing authorisation holder; 10. Date of revision of the text on 06/04/2023.
🌐 https://www.medicines.org.uk/emc/product/9488/smpc
Change log: https://www.medicines.org.uk/emc/product/9488/smpc/history

💊💉 #olaparib
SmPC for Lynparza 100 mg film-coated tablets has been updated with changes to sections on 06/04/2023.
🌐 https://www.medicines.org.uk/emc/product/9204/smpc
Change log: https://www.medicines.org.uk/emc/product/9204/smpc/history

Patienten mit metastasiertem kastrationsresistentem #Prostatakarzinom könnten von einer Behandlung mit #Olaparib profitieren: Doch nicht für alle Altersgruppen ergeben sich Vorteile, wie eine Nutzenbewertung nun zeigt. http://docc.hk/v6qm6s

💊💉 #olaparib
SmPC for Lynparza 100 mg film-coated tablets has been updated with changes to sections 4.8 Undesirable effects; 7. Marketing authorisation holder; 10. Date of revision of the text on 06/04/2023.
🌐 https://www.medicines.org.uk/emc/product/9204/smpc
Change log: https://www.medicines.org.uk/emc/product/9204/smpc/history

💊💉 #olaparib
SmPC for Lynparza 150 mg film-coated tablets has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology and method of administration; 4.4 Special warnings and precautions for use; 4.8 Undesirable effects; 5.1 Pharmacodynamic properties; 10. Date of revision of the text on 15/03/2023.
🌐 https://www.medicines.org.uk/emc/product/9488/smpc
Change log: https://www.medicines.org.uk/emc/product/9488/smpc/history

💊💉 #olaparib
SmPC for Lynparza 100 mg film-coated tablets has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology and method of administration; 4.4 Special warnings and precautions for use; 4.8 Undesirable effects; 5.1 Pharmacodynamic properties; 10. Date of revision of the text on 15/03/2023.
🌐 https://www.medicines.org.uk/emc/product/9204/smpc
Change log: https://www.medicines.org.uk/emc/product/9204/smpc/history

PARP inhibitors (#PARPi) resistance is ubiquitous in the clinic. A newly discovered pan-PARP inhibitor, thioparib, is highly effective against #olaparib -resistant cancer models, which suggests that therapeutic vulnerabilities still exist in PARPi-resistant tumors.

By JY lang, ZH Miao, A Zhang, JX He & colleagues at Chinese Academy of Sciences, Shanghai, China & University of Chinese Academy of Sciences, Beijing, China

#PARPi #CancerTherapy

👉 https://doi.org/10.15252/emmm.202216235

RT @OncBrothers@twitter.com

3 new drugs/indications were approved by @FDAOncology@twitter.com for Breast Cancer and 2 for Gyn Onc in 2022. Here is a summary!

- #TDXd x 2
- #Olaparib
- #Pembrolizumab
- #Mirvetuximab

#bcsm #gynsm @OncoAlert@twitter.com #breastcancer #MedTwitter #OncEd #MedEd #ovariancancer

🐦🔗: https://twitter.com/OncBrothers/status/1607753014521262081

Long-term data in #GeparOLA trial demonstrated similar outcome when carboplatinum was exchanged by #Olaparib as part of the neoadjuvant chemotherapy when a #BRCA mutation was present but not in wt BRCA but HRD high tumor patients. #SABCS22
Full presentation: https://www.gbg.de/wAssets/docs/geparola/2022-SABCS_GeparOla-LongtimeFU.pdf

Dr Eileen O’Reilly at #MSK ordered germline & somatic testing soon after Jay’s diagnosis with #PancreaticCancer, years before it was an #ASCO guideline. He was found to have a gBRCA1 mutation - targetable by #PARP inhibitor #olaparib - allowing a welcome chemo break. So grateful for the eight years we had post-diagnosis. #PancreasCancer
#BRCA